NCT05474755View on ClinicalTrials.gov

To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

591

Participants

Timeline

Start Date

July 28, 2022

Primary Completion Date

April 25, 2023

Study Completion Date

October 31, 2023

Conditions
Influenza
Interventions
DRUG

GP681 40mg

2X20mg tablets taken orally

DRUG

Placebo

Placebo tablets matching GP681 40mg

Trial Locations (1)

317500

The First People's Hospital of Wenling, Wenling

Sponsors
All Listed Sponsors
lead

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

INDUSTRY